Typhoid conjugate vaccine (Vi-CRM197) - Novartis Vaccines Institute for Global Health

Drug Profile

Typhoid conjugate vaccine (Vi-CRM197) - Novartis Vaccines Institute for Global Health

Alternative Names: NVGH glycoconjugate vaccine against S. typhi - Novartis; NVGH Vi-CRM197 vaccine; Salmonella monovalent typhi vaccine - NVGH; Typhoid conjugate vaccine - Novartis; Vi-CRM(197); Vi-CRM197 glycoconjugated vaccine; Vi-CRM197 vaccine

Latest Information Update: 19 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis Vaccines Institute for Global Health
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Typhoid

Most Recent Events

  • 19 Aug 2015 No recent reports on development identified - Phase-II for Typhoid (In children, In infants, Prevention) in Philippines (Parenteral)
  • 19 Aug 2015 No recent reports on development identified - Phase-II for Typhoid (Prevention, In adults) in Belgium (Parenteral)
  • 19 Aug 2015 No recent reports on development identified - Phase-II for Typhoid (Prevention) in India and Pakistan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top